688180 君实生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-6.747-19.689-27.454-27.404-10.469
总资产报酬率 ROA (%)-3.675-11.579-19.107-20.243-7.576
投入资产回报率 ROIC (%)-4.310-14.041-22.727-24.558-9.379

边际利润分析
销售毛利率 (%)80.06078.92163.99665.30469.079
营业利润率 (%)-40.655-68.717-163.551-183.414-13.871
息税前利润/营业总收入 (%)-39.342-69.686-170.296-189.759-14.004
净利润/营业总收入 (%)-39.856-70.836-168.759-177.784-18.151

收益指标分析
经营活动净收益/利润总额(%)101.13693.36992.68098.964118.222
价值变动净收益/利润总额(%)-7.2615.2473.0181.913-11.050
营业外收支净额/利润总额(%)2.1021.3801.3750.4216.172

偿债能力分析
流动比率 (X)1.6121.7182.2854.0862.920
速动比率 (X)1.4241.4832.0643.7462.678
资产负债率 (%)45.25244.98135.46122.15324.636
带息债务/全部投入资本 (%)32.17830.45318.73910.6975.317
股东权益/带息债务 (%)194.468214.602411.315819.6341,731.442
股东权益/负债合计 (%)120.609120.838177.791340.888292.256
利息保障倍数 (X)-17.9939,401.88438.14234.070-17.970

营运能力分析
应收账款周转天数 (天)79.81591.74586.422189.63784.232
存货周转天数 (天)440.924491.996378.341386.772119.759